TheBrief.Health
Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.
518 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der TheBrief.Health-Community!